GENUI and SHS Capital have jointly invested in ROTOP Pharmaka GmbH, a leading European manufacturer of radiopharmaceuticals, to enhance the company's production capabilities and expand its market presence.
Information on the Target
ROTOP Pharmaka GmbH is a prominent manufacturer and Contract Development and Manufacturing Organization (CDMO) specializing in radiopharmaceuticals. Founded in 2000 and located in Dresden-Rossendorf, Germany, ROTOP has established itself as a key player in the European market for radiopharmaceutical products. The company focuses on the development and production of radioactive drugs, which are increasingly utilized for both diagnostic and therapeutic applications in modern medicine.
With advancements in nuclear medicine, ROTOP has positioned itself at the forefront of innovation and quality. The range of products offered by ROTOP includes both established radioisotopes for imaging and novel compounds that hold therapeutic potential, underscoring its commitment to improving patient outcomes through leading-edge medical solutions.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
The radiopharmaceutical industry in Germany is witnessing significant growth, fueled by advancements in imaging technologies and the rising demand for precise diagnosis and targeted therapies. As one of the leading markets for nuclear medicine in Europe, G
Similar Deals
Springboard Health Angels, Pluton Asset Holding AG, Sintra Ventures, Technologiegründerfonds Sachsen, i&i Bio, HIL-INVENT, Brandenburg Kapital → Captain T Cell
2025
Picus Capital, Alven, Heliad, Rubin Ritter, Lars Langusch, Jens Begemann, Debiopharm, Arve Capital, Christoph Haarburger → StratifAI
2025
GENUI und SHS Capital
invested in
ROTOP
in 2025
in a Other VC deal